Skyclarys Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9670147 REATA PHARMS Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
Apr, 2029

(4 years from now)

US8124799 REATA PHARMS Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
Dec, 2029

(5 years from now)

US9701709 REATA PHARMS 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
Apr, 2033

(8 years from now)

US8993640 REATA PHARMS 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
Apr, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11919838 REATA PHARMS Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
Apr, 2029

(4 years from now)

US11091430 REATA PHARMS Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
Apr, 2029

(4 years from now)

US8440854 REATA PHARMS Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17
Apr, 2029

(4 years from now)



Skyclarys is a drug owned by Reata Pharmaceuticals Inc. It is used for treating Friedrich's ataxia by activating the NRF2 pathway to reduce oxidative stress in adults and adolescents aged 16 years and older. Skyclarys uses Omaveloxolone as an active ingredient. Skyclarys was launched by Reata Pharms in 2023. It is is available in capsule form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 24, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 28, 2028
Orphan Drug Exclusivity(ODE-427) Feb 28, 2030

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using OMAVELOXOLONE ingredient

NCE-1 date: 28 February, 2027

Market Authorisation Date: 28 February, 2023

Treatment: Method of treating friedrich's ataxia by activating the nrf2 pathway which reduces oxidative stress; Treatment of friedreich's ataxia in adults and adolescents aged 16 years and older

Dosage: CAPSULE

More Information on Dosage

SKYCLARYS family patents

Family Patents